| Identification | Back Directory | [Name]
N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide | [CAS]
1418112-77-2 | [Synonyms]
AZD-4721
EOS-61288
Vimnerixin
Vimnerixin (AZD4721
N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide
1-Azetidinesulfonamide, N-[6-[(1R,2S)-2,3-dihydroxy-1-methylpropoxy]-2-[[(4-fluorophenyl)methyl]thio]-4-pyrimidinyl]-3-methyl- | [Molecular Formula]
C19H25FN4O5S2 | [MOL File]
1418112-77-2.mol | [Molecular Weight]
472.55 |
| Hazard Information | Back Directory | [Uses]
Vimnerixin (AZD4721) is the potent and orally active antagonist of acidic CXC chemokine receptor 2 (CXCR2). Vimnerixin has the potential for the research of inflammatory disease[1]. | [in vivo]
Assessment of Pharmacokinetics (PK) profile of Vimnerixin in rat and dog[1]
.
| In Vivo PK | Rat | Dog | | Predicted hepatic metabolic CL (ml/min per kilogram) | 1.7 | 0.80 | | Observed CL (ml/min per kilogram) | 2.4 | 0.50 | | CLrenal (mL/min per kilogram) | <0.01 | <0.01 | | CLbiliary (mL/min per kilogram) | <0.01 | 0.04 | | In vivo/in vitro unbound CLintc | 1.4 | 0.6 | | VSS (l/kg) | 0.19 | 0.15 | | T1/2 (h) (PO) | 1.3 | 3.7 | | (2.7) | (8.4) | | F (%) | 45 | 82 |
| [storage]
Store at -20°C | [References]
[1] Gardiner P, et al. Plasma Protein Binding as an Optimizable Parameter for Acidic Drugs. Drug Metab Dispos. 2019;47(8):865-873. DOI:10.1124/dmd.119.087163 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|